厄贝沙坦联合非洛地平治疗41例原发性高血压患者的疗效观察及药物经济学分析

Analysis of Clinical Efficacy and Pharmacoeconomics of Irbesartan and Felodipine in the Treatment of 41 Cases of Patients with Primary Hypertension

目的:探讨厄贝沙坦联合非洛地平治疗原发性高血压患者的疗效及药物经济学价值。方法:选取2015年3月~2017年3月郑州煤炭工业(集团)有限责任公司总医院82例原发性高血压患者,随机数字表法分组,各41例。对照组予以非洛地平,研究组予以厄贝沙坦+非洛地平,两组均持续治疗1个月。统计对比两组临床疗效、不良反应、药物成本-疗效。结果:经秩和检验,研究组治疗有效率97.56%(40/41)高于对照组70.73%(29/41),差异有统计学意义(P<0.05);研究组不良反应发生率14.63%(6/41)与对照组19.51%(8/41)相比,差异无统计学意义(P>0.05);研究组治疗成本、成本-疗效比值明显低于对照组,差异有统计学意义(P<0.05)。结论:厄贝沙坦联合非洛地平治疗原发性高血压患者疗效显著,且具有较高安全性及药物经济学价值。

Objective:To investigate the Curative effect and the value of Pharmacoeconomics of irbesartan and felodipine in treatment of patients with primary hypertension.Methods:A total of 82 cases of primary hypertension in our hospital from March 2015 to March 2017 were divided into groups by random digital table method with 41 cases in each.The control group was treated with felodipine,the study group was treated with irbesartan and felodipine,and the two groups were treated for 1 month.The clinical effects,adverse reactions,drug cost and efficacy of two groups were statistically compared.Results:The rank sum test showed that,the efficacy rate of the study group was 97.56%(40/41),higher than that of the control group(70.73%)(29/41),and the difference was statistically significant(P<0.05).There were insignificant differences in the incidence of adverse reaction between the study group 14.63%(6/41)and control group 19.51%(8/41)(P<0.05).The cost of treatment,the ratio of cost to curative effect in the study group were significantly lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion:Irbesartan and felodipine in the treatment of primary hypertension patients has significant curative effect,high safety and high pharmacoeconomic value.